ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MGNX MacroGenics Inc

4.365
-0.755 (-14.75%)
After Hours
Last Updated: 16:30:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,848,922
Bid Price 4.37
Ask Price 4.41
News -
Day High 5.20

Low
3.14

52 Week Range

High
21.88

Day Low 4.34
Company Name Stock Ticker Symbol Market Type
MacroGenics Inc MGNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.755 -14.75% 4.365 16:30:00
Open Price Low Price High Price Close Price Prev Close
5.08 4.34 5.20 4.365 5.12
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
23,144 3,848,922 $ 4.72 $ 18,165,885 - 3.14 - 21.88
Last Trade Time Type Quantity Stock Price Currency
16:33:32 1 $ 4.38 USD

MacroGenics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
278.45M 62.43M - 58.75M -9.06M -0.15 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MacroGenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MGNX Message Board. Create One! See More Posts on MGNX Message Board See More Message Board Posts

Historical MGNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.535.203.143.8813,457,063-0.165-3.64%
1 Month15.9616.5853.146.074,179,291-11.60-72.65%
3 Months17.1321.883.1411.082,559,248-12.77-74.52%
6 Months7.2821.883.1411.571,691,080-2.92-40.04%
1 Year6.0921.883.149.961,125,244-1.73-28.33%
3 Years29.3732.812.1310.13882,888-25.01-85.14%
5 Years17.8136.48042.1314.59896,754-13.45-75.49%

MacroGenics Description

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.